Tvardi Therapeutics
TVRD
81 hedge funds and large institutions have $95.5M invested in Tvardi Therapeutics in 2016 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 9 closing their positions.
543% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $220K
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
16% more funds holding
Funds holding: 70 → 81 (+11)
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $120M → $95.5M (-$24.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.49M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$1.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.01M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$809K |
| 5 |
Morgan Stanley
New York
|
+$783K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$5.01M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$2.67M |
| 3 |
Millennium Management
New York
|
-$2.12M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$963K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$693K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCIM
76
TIAA CREF Investment Management
New York
| $1.34K | +$161K | +745 | +20% |
|
77
Barclays
London,
United Kingdom
| $1K | -$1.73K | -8 | -67% |
|
|
MTIP
78
Magee Thomson Investment Partners
San Diego,
California
| $1K | +$433 | +2 | +100% |
|
79
VOYA Investment Management
Atlanta,
Georgia
| $89 | – | – | – |
|
|
PAMU
80
Pictet Asset Management (UK)
London,
United Kingdom
| – | -$5.01M | -21,553 | Closed |
|
|
81
Millennium Management
New York
| – | -$2.12M | -12,267 | Closed |
|
|
BIM
82
Bogle Investment Management
Newton Lower Falls,
Massachusetts
| – | -$642K | -3,710 | Closed |
|
83
D.E. Shaw & Co
New York
| – | -$90K | -521 | Closed |
|
|
TI
84
Trexquant Investment
Stamford,
Connecticut
| – | -$77K | -443 | Closed |
|
85
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$63K | -364 | Closed |
|
|
KF
86
Krilogy Financial
St. Louis,
Missouri
| – | -$8K | -44 | Closed |
|
|
PAM
87
Panagora Asset Management
Boston,
Massachusetts
| – | -$7K | -42 | Closed |
|
|
AIM
88
Advantage Investment Management
Cedar Rapids,
Iowa
| – | +$217 | +1 | New |
|
TVRD Hedge Fund Activity: Q3 2016 in Review
81 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2016, worth a combined $95.5M — down 21% from $120M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TVRD positions and 9 closed out — a net gain of 12 holders — while 20 added to existing stakes and 18 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.49M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $5.01M sold.
- 81 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2016, up from 70 in Q2 2016.
- Funds reported $95.5M of Tvardi Therapeutics stock for Q3 2016, down 21% quarter-over-quarter.
- 21 funds opened new Tvardi Therapeutics positions in Q3 2016 and 9 closed out, a net change of +12 holders.
- The largest Tvardi Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $1.49M added.
- The largest Tvardi Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $5.01M sold.
Based on aggregated 13F filings for Q3 2016.